The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| Acceleron Pharma Inc. | COM | 00434H108 | 2,440 | 50,047 | SH | SOLE | 50,047 | 0 | 0 | ||
| Acceleron Pharma Inc. | COM | 00434H108 | 4,876 | 100,000 | SH | Put | SOLE | 100,000 | 0 | 0 | |
| Aerie Pharmaceuticals, Inc. | COM | 00771V108 | 5,668 | 232,757 | SH | SOLE | 232,757 | 0 | 0 | ||
| Aimmune Therapeutics, Inc. | COM | 00900T107 | 6,550 | 355,020 | SH | SOLE | 355,020 | 0 | 0 | ||
| Akari Therapeutics, PLC | SPONSORED ADR | 00972G108 | 3,827 | 263,921 | SH | SOLE | 263,921 | 0 | 0 | ||
| Alder BioPharmaceuticals, Inc. | COM | 014339105 | 7,593 | 229,895 | SH | SOLE | 229,895 | 0 | 0 | ||
| Dimension Therapeutics, Inc. | COM | 25433V105 | 1,109 | 98,297 | SH | SOLE | 98,297 | 0 | 0 | ||
| Dyax Corp | COM | 26746E103 | 2,103 | 55,900 | SH | Call | SOLE | 55,900 | 0 | 0 | |
| Epizyme, Inc. | COM | 29428V104 | 7,396 | 461,651 | SH | SOLE | 461,651 | 0 | 0 | ||
| Global Blood Therapeutics, Inc. | COM | 37890U108 | 14,872 | 460,000 | SH | SOLE | 460,000 | 0 | 0 | ||
| ImmunoGen, Inc. | COM | 45253H101 | 581 | 42,815 | SH | SOLE | 42,815 | 0 | 0 | ||
| Intersect ENT, Inc. | COM | 46071F103 | 4,500 | 200,000 | SH | SOLE | 200,000 | 0 | 0 | ||
| Lipocine Inc. | COM | 53630X104 | 4,267 | 330,000 | SH | SOLE | 330,000 | 0 | 0 | ||
| NeuroDerm Ltd. | ORD SHS | M74231107 | 4,466 | 261,945 | SH | SOLE | 261,945 | 0 | 0 | ||
| Orexigen Therapeutics, Inc. | COM | 686164104 | 5,160 | 3,000,000 | SH | SOLE | 3,000,000 | 0 | 0 | ||
| Regenxbio Inc. | COM | 75901B107 | 1,660 | 100,000 | SH | SOLE | 100,000 | 0 | 0 | ||
| Regulus Therapeutics Inc. | COM | 75915K101 | 6,270 | 718,997 | SH | SOLE | 718,997 | 0 | 0 | ||
| WAVE Life Sciences Ltd. | SHS | Y95308105 | 22,500 | 1,410,689 | SH | SOLE | 1,410,689 | 0 | 0 | ||
| Zafgen, Inc. | COM | 98885E103 | 6,917 | 1,099,700 | SH | SOLE | 1,099,700 | 0 | 0 | ||